Khan Najat sold $84K of RXRX
Khan Najat (CEO and President) sold 23,588 shares of RECURSION PHARMACEUTICALS, INC. (RXRX) at $3.58 on 2026-06-05 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosed sale can influence short-term sentiment, but 10b5-1 pre-arrangement typically lowers the likelihood of it signaling new negative information.
Market read
A same-day insider selling print for RXRX, partially mitigated by the stated 10b5-1 plan.
What to watch
Consider whether other insiders also sold around the same window and whether there are concurrent clinical/regulatory updates not mentioned here.
Background
The article is an SEC Form 4 insider transaction disclosure for Recursion Pharmaceuticals’ CEO/President.
Ticker impact
Recursion Pharmaceuticals CEO/President Khan Najat sold 23,588 shares in an open-market transaction disclosed via SEC Form 4.
Likely limited immediate price impact; watch for follow-on insider activity or concurrent fundamental catalysts.
This is an ownership-change disclosure with transaction details, but it is explicitly under a pre-arranged 10b5-1 plan, which typically dampens signal strength versus discretionary sales.
Market effects
Adds marginal sentiment noise for biotech/clinical-stage names where insider selling can be interpreted as risk appetite.
None specific beyond US small/mid-cap biotech tape.
Limited; this is company-specific insider activity.
Counterpoint
Because the sale is under a pre-arranged 10b5-1 plan, it may reflect routine liquidity rather than bearish fundamentals.
Key entities
- companyRecursion Pharmaceuticals, Inc.
Issuer of the insider transaction; CEO/President sold shares via open-market sale under a 10b5-1 plan.
- personKhan Najat
CEO and President; reported the sale of 23,588 shares at $3.5806/share.
